Oxurion NV — Director's Dealing 2023

Nov 15, 2023

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM, Boston, MA, US – November 15, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on November 14, 2023, from Atlas Special Opportunities, LLC indicating that as of November 3, 2023, it held 232,919,254 shares of the then outstanding 2,956,764,011 shares, and therefore crossed above the threshold (5%) by virtue of the acquisition of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forwardlooking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

________

Oxurion NV	US
Tom Graney	Conway Communications
Chief Executive Officer	Mary T. Conway
Tel: +32 16 75 13 10	mtconway@conwaycommsir.com
tom.graney@oxurion.com
Michael Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
Final
2) Issuer
Name OXURION 0881-620-924 Identification number
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights		$+$
4) Notification by
A person that notifies alone
5) Persons subject to the notification requirement
Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name	Address (for legal entities)
Please continue entering the information in part II concerning the Part II persons referred to in Sections 5 and 6
7) Date on which the threshold is crossed
03/11/2023 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
$\overline{5}$
If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

10) Notified details

A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	31.523.659	232.919.254	0	7.88%	0.00%
TOTAL		232,919,254	0	7.88%	0.00%

$\pm$

Start with "groups" of holders. Add subtotals with $\Sigma$ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be

.
gn Envelope ID: 8A947BFC-FF5F-4D07-837C-1E1A976852E6

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL			O	0.00%

The totals will be updated once you have clicked on

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	232.919.254	7.88%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

alder	will cease to hold / чадал.	voting rights as of

13) Additional information

On 3 November 2023, Atlas Special Opportunities LLC held 77,639,751 shares (= 2.63% with denomintaor = 2,956,764,011) in Oxurion NV. On the same day, Atlas Special Opportunities LLC bough 155,279,503
shares in Oxurion NV, as a result of which its shareholding increased to 232,919,254 shares (= 7.88% with denominator 2,956,764,011)

	Done at New York
On		10/11/2023 (DD/MM/YYYY)
	Name & capacity Patrick Vance, proxyholder

Signature Patrick Vance